Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AU2018257624B2 - Oral microbiota promoting composition and method - Google Patents
[go: Go Back, main page]

AU2018257624B2 - Oral microbiota promoting composition and method - Google Patents

Oral microbiota promoting composition and method Download PDF

Info

Publication number
AU2018257624B2
AU2018257624B2 AU2018257624A AU2018257624A AU2018257624B2 AU 2018257624 B2 AU2018257624 B2 AU 2018257624B2 AU 2018257624 A AU2018257624 A AU 2018257624A AU 2018257624 A AU2018257624 A AU 2018257624A AU 2018257624 B2 AU2018257624 B2 AU 2018257624B2
Authority
AU
Australia
Prior art keywords
composition
oral
oral cavity
sugar
microbiota
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018257624A
Other versions
AU2018257624A1 (en
Inventor
Shunsheng Han
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Knoze Jr Corp
Original Assignee
Knoze Jr Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoze Jr Corp filed Critical Knoze Jr Corp
Publication of AU2018257624A1 publication Critical patent/AU2018257624A1/en
Application granted granted Critical
Publication of AU2018257624B2 publication Critical patent/AU2018257624B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/175Amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004Monosaccharides having only carbon, hydrogen and oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/719Pullulans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733Fructosans, e.g. inulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/304Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00Function of food ingredients
    • A23V2200/30Foods, ingredients or supplements having a functional effect on health
    • A23V2200/314Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11Medicinal preparations comprising living procariotic cells
    • A61K2035/115Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method of promoting a desired oral microbiota in a subject to treat an allergy related respiratory condition, the method including providing an edible composition including an amino acid containing ingredient comprising L-arginine wherein the composition is provided contained and at least partially dissolved within an oral cavity of the subject for a period of at least from about 10 seconds to about an hour on a daily basis of at least two consecutive days.

Description

Oral Microbiota Promoting Composition and Method
[001] The disclosure generally relates to oral cavity
microbiota promoting compositions including sweetened prebiotic foods and methods for making and using the same. More
particularly, the disclosure relates to compositions and methods for making and using the same that may have the advantageous
effect of modulating the oral microbiota which may thereby
promote the naturally occurring health of the immune system including reducing respiratory allergic reactions.
BACKGROUND
[002] In general, the prevalence of allergic diseases has dramatically increased in recent decades and currently affects
more than sixty million people in the United States, reducing the quality of life. It is believed and has been found that the
presence of certain oral bacteria species/strains may affect the aggressiveness of response of the immune system, for example
with respect to allergies. More specifically, while not intending to be bound by any health claims, it is believed that the reduction of normally occurring oral bacteria in the
normally occurring oral microbiota, for example, by aggressive dental hygiene practices, may serve to make non-pathogenic
antigens, such as pollen, more prevalent and visible to the
immune system. It is further believed, that as a result, non
pathogenic antigens, such as those related to allergens may be more readily targeted by the immune system, leading to exacerbated allergic reactions.
[003] For example, oral hygiene hypothesis (OHH) is one
aspect of a more general hygiene hypothesis (HH), which was
proposed more than two decades ago ( see Strachan, D.P. "Hay
1 SUBSTITUTE SHEET (RULE 26) fever, hygiene, and household size", British Medical Journal 299, 1259-1260 (1989)) to explain the rise in allergic diseases.
Numerous scientific studies have since provided support for HH, generally showing a relation between increased exhibition of
allergies in association with modern social practices, such as
formula infant feeding, antibiotic use, urban living, and reduction in family size (see e.g., Okada, H., Kuhn, C.,
Feillet, H. & Bach, J.F., "The hygiene hypothesis for autoimmune and allergic diseases: an update" Clin. Exp. Immunol. 160, 1-9
(2010)). Although the molecular mechanisms of immune system modulation by gut microbiota are well understood, efforts to reduce allergic reactions through microbial intervention, such
as by the use of probiotics have shown inconsistent results.
[004] Extensive oral hygiene practices, according to oral hygiene hypothesis (Han, CS., "A specific hygiene hypothesis"
Med. Hypotheses 2016 Aug; 93:146-149), are believed to cause
related the exacerbation of naturally occurring respiratory allergies, such as allergic rhinitis (AR), one of the most
common allergic conditions.
[005] There is therefore a need for a composition including an oral cavity microbiota promoting substance and method of
using the same that has the effect of promoting a healthy oral
microbiota that promotes the healthy operation of the immune system which may have the functional effect of promoting an improved response to allergens.
[006] It is an object of the invention to provide a
composition including an oral cavity microbiota promoting substance and method of using the same that has the effect of
promoting a healthy oral microbiota that promotes the healthy
2 SUBSTITUTE SHEET (RULE 26) operation of the immune system which may have the functional effect of promoting an improved response to allergens.
SUMMARY
[007] A use of a product in the preparation of a medicament for
promoting a desired oral microbiota to treat an allergy related
respiratory condition in a subject in need of such treatment
comprising: providing a prebiotic edible composition comprising an
amino acid containing ingredient comprising individual molecules of
L-arginine and a sugar containing ingredient, the sugar comprising
one or more of monosaccharides, disaccharides, oligosaccharides, and
polysaccharides; removing a biofilm from surfaces within an oral
cavity by heating the inside of the oral cavity to a temperature of
about 37 deg C. to about 55 deg C.; wherein following removal of the
biofilm, the composition is provided contained and at least partially
dissolved within an oral cavity of the subject for a period of at
least from about 10 seconds to about an hour on a daily basis of at
least two consecutive days to promote an increased concentration of
selected oral microbiota, the selected microbiota comprising
Veillonella and Streptococcus, to thereby treat an allergy related
respiratory condition.
DETAILED DESCRIPTION
[008] The following detailed description is merely exemplary in
nature and is not intended to limit the described embodiments or the
application and uses of the described embodiments. As used herein,
the word "exemplary" or "illustrative" means "serving as an example,
instance, or illustration.'' Any implementation described herein as "exemplary" or "illustrative" is not necessarily to be construed as
preferred or advantageous over other implementations. All of the
implementations described below are exemplary implementations
provided to enable persons skilled in the art to practice the
disclosure and are not intended to limit the scope of the appended
claims. Furthermore, there is no intention to be bound by any expressed
or implied theory presented in the preceding technical field,
background, brief summary or the following detailed description.
[009] It is believed, and has been found that according to the oral hygiene hypothesis (OHH) noted above, that persistent and intensive hygiene practices, together with other life events, such as fever and/or antibiotic usage, will likely change the oral microbiota of an individual. The oral cavity is a complex environment with many different biological niches, such as the tongue, gum, and teeth. Normally occurring microbiota associated with these niches are different and are believed to have a different effect on normal functioning of the immune system.
[0010] Likewise, it is believed, and has been unexpectedly found, that the introduction of selected microbiota-promoting
substances into the oral cavity in a controlled manner, may
promote desired naturally occurring oral bacteria species/strains, which may in turn have an associated effect of
modulating or reducing the intensity of certain types of
allergic reactions, including those associated with allergic rhinitis (AR) one of the most common allergic reactions
including symptoms such as any combination of a runny or stuffy nose, sneezing, itchy/red eyes, coughing, and congestion.
[0011] While not intending to be bound by any particular
theory of operation, and making no specific health claims, it is believed that oral microbiota interact with the host largely
through metabolites produced by its relevant bacterial members.
Those metabolites, such as but not limited to short chain fatty
acid, may influence the function of multiple biologic systems and organs, such as the immune system. Missing or severe
reduction of the relevant bacteria may cause malfunctioning of
the immune system, such as causing over sensitivity to allergens.
4 SUBSTITUTE SHEET (RULE 26)
[0012] Therefore, it is believed that the immune system
response to the allergen may be modulated such that the
associated allergic reaction symptoms are suppressed relative to what an allergic reaction may be with an unhealthy level of or
different microbiota. It is further believed and evidence
suggests that over time, as a result of promoting a healthy oral microbiota with selected microbiota-promoting substances that
the immune system may function in a healthy manner with a healthy response to allergens.
[0013] Furthermore, due to the connectivity among mouth and respiratory duct and lungs, a healthy oral microbiota may lead
to a healthy microbiota in the lungs as well. Eventually the
method may benefit the healthy functioning of the immune system which may in turn have a healthy response not only to allergic
rhinitis but also the relevant diseases in the lungs, such as
asthma.
[0014] In one embodiment, an oral microbiota promoting
composition may be provided into an oral cavity that may have the effect of promoting desired microbiota within an oral cavity.
[0015] In another embodiment, a method of applying an oral microbiota promoting composition (prebiotic) may be provided
that may have the effect of promoting desired microbiota within an oral cavity and have the desired functional effect of
treating a respiratory condition including allergic rhinitis.
[0016] In one embodiment, a method of applying an oral
microbiota promoting composition may include multiple instances
of introduction of the composition into the oral cavity (mouth)
5 SUBSTITUTE SHEET (RULE 26) in the form or a solid, powder, paste, or liquid in the amount of about 1 gm to about 500 gms at one time or multiple times in fractional amounts. Where the oral microbiota promoting composition is in the form of liquid, the method may include dissolving the composition in a liquid
[0017] In another embodiment, a method of applying an oral
microbiota promoting composition may include swallowing the
composition following introduction of the composition into the oral cavity and following a period of retaining the composition within the mouth for a select period of time including e.g., chewing, gargling, and/or sublimating (dissolving) the
composition while within the oral cavity.
[0018] In another embodiment, a method of applying an oral microbiota promoting composition may include removing the
composition following introduction into the oral cavity by
expelling (e.g., pulling out or spitting-out) the microbiota promoting composition following a period of retaining the
composition within the mouth.
[0019] In another embodiment, a method of applying an oral
microbiota promoting composition may include retaining the microbiota promoting composition within the oral cavity from about 10 seconds to about an hour, more preferably, from about 5
minutes to about 30 minutes on a daily basis for a period of about 2 days to about 60 days.
[0020] In another embodiment, a method of applying an oral microbiota promoting composition may include introducing the
microbiota promoting composition for relatively short periods
several times a day, for example from about 1 second to about 30
6 SUBSTITUTE SHEET (RULE 26) seconds, each from about 3 to about 10 times a day for a period of about 2 days to about 60 days.
[0021] In another embodiment, a method of applying an oral microbiota promoting composition may include extending the
periods of introduction of the microbiota promoting composition into the oral cavity, for example, from about every 3 days to
about every 10 days, including stopping the introduction of the
composition following the disappearance of allergy symptoms.
[0022] In another embodiment, a method of applying an oral
microbiota promoting composition may include at least partially removing a mucosal film (biofilm) from within the oral cavity prior to or while administering the microbiota promoting
composition to the oral cavity.
[0023] It will he appreciated that the hiofilm may be at
least partially removed by raising the whole body temperature
for a short time, for example, with conventional biological or physical means.
[0024] In a related embodiment, the biofilm may be at least partially removed by rinsing out (optionally including scrubbing
or rubbing) the oral cavity (mouth) with a heated water
containing liquid, such as water, at a temperature of from about 90 to about 130 degrees Fahrenheit prior to applying the oral
microbiota promoting composition to the oral cavity. It will be appreciated that rinsing with a hot water containing fluid as
noted may advantageously at least partially remove a biofilm from surfaces within the oral cavity, thereby improving the
operation of the oral microbiota promoting composition. The
oral rinsing may include periodic rinsing, for example, each for
7 SUBSTITUTE SHEET (RULE 26) about 10 seconds to about 30 seconds over a period of from about
5 to about 15 minutes.
[0025] In another embodiment, a method of applying an oral microbiota promoting composition may include at least one of
brushing and rubbing portions of the oral cavity with the hot water containing fluid at a temperature of from about 100 to
about 130 degrees Fahrenheit including at least the tongue, for
example, with at least one of a brush, such as a toothbrush, and/or a wet cloth.
[0026] In another embodiment, the oral microbiota promoting composition may be formulated into oral dosage forms such as tablets, caplets, and capsules, or a powder formulation or that
may be dissolved in a liquid, for example diluted in a liquid having a ratio of from about 1:1 to about 1:500 with respect to
either weight or volume of the liquid (e.g., the liquid being
larger number).
[0027] In another embodiment, the oral microbiota promoting
composition may be formulated or manufactured as a chewing gum or candy, or other edible carrier, for example as an additive
having a ratio of from about 1:1 to about 1:500 with respect to either weight or volume of the edible carrier (e.g., larger number) .
[0028] In another embodiment, the oral microbiota promoting composition may be formulated as an additive to an oral hygiene
product acting as a carrier, such as toothpaste or mouthwash, the microbiota promoting composition having a ratio of from about 1:1 to about 1:500 with respect to either weight or volume
of the oral hygiene product.
8 SUBSTITUTE SHEET (RULE 26)
[0029] In another embodiment, in a method of manufacturing an oral microbiota promoting composition may be formulated having
an edible foodstuff as a carrier, the microbiota promoting composition having a ratio of from about 1:1 to about 1:500 with
respect to either weight or volume of the edible foodstuff.
[0030] In one embodiment, the desired microbial
species/strains promoted in the oral cavity by the oral
microbiota promoting composition may be naturally occurring within the oral cavity and/or may be provided separately or within the oral microbiota promoting composition.
[0031] In a related embodiment, the desired microbial species/strains are present in the oral cavity or in the oral
microbiota promoting composition at a level of from about 1000 to about 1,000,000,000 living cells.
[0032] It will be appreciated that the desired microbial
species/strains are naturally occurring and/or may be obtained commercially and handled in accordance with any applicable
safety requirements,
[0033] In another embodiment, the desired microbial
species/strains promoted in the oral cavity by the oral
microbiota promoting composition may include at least a first microbial species that can attach to surfaces (e.g., teeth,
tongue, mouth) within the oral cavity and at least one second microbial species that may attach to the same or different
surfaces and/or may attach to the at least first microbial species.
9 SUBSTITUTE SHEET (RULE 26)
[0034] In a related embodiment, the at least a first and
second microbial species may produce a product, such as a sugar containing moiety, that may be metabolized by the other of the at least a first and second microbial species.
[0035] In one embodiment, one of the desired microbial members promoted within the oral cavity promoted by the oral
microbiota promoting composition may include one or more live
bacterium with lactate fermenting capability such as, but not limited to Veillonella, which further may include one or more of associated species, such as, but not limited to, V. Dispar and V. Parvula.
[0036] In one embodiment, one of the desired microbial
species/strains promoted within the oral cavity promoted by the oral microbiota promoting composition may include one or more
live lactic acid producing bacterium such as but not limited to
Streptococcus including one or more of associated species, such as, but not limited to, S. salivarius and S. thermophilus.
[0037] In a related embodiment, the desired microbial species/strains promoted within the oral cavity by the oral
microbiota promoting composition may include at least one live lactic acid producing bacterium and at least one live lactate fermenting bacterium such as, but not limited to, respectively,
Veillonella and Streptococcus and their respectively associated preferred species stated above.
[0038] In another embodiment, an oral microbiota promoting composition is provided that includes at least one amino acid
or amino acid containing substance including at least L
arginine. The at least one amino acid may further or
10 SUBSTITUTE SHEET (RULE 26) alternately include at least one of L-cysteine, DL-aspartic acid, L-glutamic acid, L-serine and L-tyrosine including phosphates, salts, acids, and enzymes comprising the same.
[0039] In a related embodiment, the at least one amino acid,
may be present in the oral microbiota promoting composition at a weight percent level of from about 0.1 wt. % to about 99.9 wt.
%, more preferably, from about 5 wt % to about 95 wt %, even
more preferably from about 20 wt % to 80 wt %.
[0040] In another embodiment, an oral microbiota promoting composition is provided that includes at least one sugar containing substance and at least one amino acid containing substance. The at least one sugar containing substance may
include at least one monosaccharide, disaccharide, oligosaccharide, and polysaccharide. .
[0041] Exemplary monosaccharides may include but are not
limited to aldohexoses such as but not limited to mannose including associated isomers, phosphates, salts, acids, and
enzymes comprising the same.
[0042] Exemplary disaccharides may include but are not
limited to disaccharides including at least one of galactose and
glucose, such as but not limited to lactose, sucrose, malibiose, maltose, cellobiose and trehalose (also known as mycose or
tremalose) including associated isomers, phosphates, salts, acids, and enzymes comprising the same.
[0043] Exemplary oligosaccharides may include but are not limited to trisaccharides including at least one or more of
galactose, glucose, and fructose, such as but not limited to
11 SUBSTITUTE SHEET (RULE 26) raffinose (also known as melitose), stachyose, and verbascose, including associated isomers, phosphates, salts, acids, and enzymes comprising the same.
[0044] Further, Exemplary polysaccharides may include but are
not limited to one or more polysaccharide polymers, such as, but not limited to polysaccharides including malotriose units,
including but not limited to pullulan, and fructose polymers,
such as, but not limited to inulin and further including associated isomers, phosphates, salts, acids, and enzymes comprising the same.
[0045] In a related embodiment, the at least one disaccharide may be present in the oral microbiota promoting composition at a
weight percent level of from about 0.1 wt. % to about 99.9 wt. %, more preferably, from about 5 wt % to about 95 wt %, even
more preferably from about 20 wt % to 80 wt %.
[0046] In a related embodiment, the at least one oligosaccharide may be present in the oral microbiota promoting
composition at a weight percent level of from about 0.1 wt. % to about 99.9 wt. %, more preferably, from about 5 wt % to about 95
wt %, even more preferably from about 20 wt % to 80 wt %.
[0047] In a related embodiment, the at least one polysaccharide may be present in the oral microbiota promoting
composition at a weight percent level of from about 0.1 wt. % to about 99.9 wt. %, more preferably, from about 5 wt % to about 95
wt %, even more preferably from about 20 wt % to 80 wt%.
12 SUBSTITUTE SHEET (RULE 26)
[0048] In another embodiment, the oral microbiota promoting
composition may include at least one prebiotic fiber. Exemplary prebiotic fibers may include but are not limited to inulin.
[0049] In a related embodiment, the at least one prebiotic
fiber may be present in the oral microbiota promoting composition at a weight percent level of from about 0.1 wt. %- to
about 99.9 wt. %, more preferably, from about 5 wt % to about 95
wt %, even more preferably from about 10 wt % to 30 wt %.
[0050] In another embodiment the oral microbiota promoting composition may include additives such as one or more of carbohydrates, amino acids, salts, flavorants, proteins, surfactants, emulsifiers, flavonoids, alcohols, synthetic
sweeteners, food preserving agents, and combinations thereof.
[0051] In one embodiment, the oral microbiota promoting
composition may further include conventional foodstuffs such as
one or more of brown sugar, syrup, honey, chocolate, nuts, almonds, spices, cinnamon, and vanilla.
[0052] In a specific exemplary embodiment, an example of making an edible Foodstuff oral microbiota promoting composition
is provided below in Example 1:
[0053] Example 1:
[0054] 1 cup raffinose
[0055] 1 cup trehalose
[0056] 2 tablespoons mannose
[0057] 1 cup lactose
13 SUBSTITUTE SHEET (RULE 26)
[0058] 4 cup maltose
[0059] 4 cup arginine
[0060] 2 tablespoons pullulan
[0061] 1 cup inulin
[0062] 1 cup dark brown sugar
[0063] b cup corn syrup
[0064] 4 cup honey
[0065] 1 cup milk chocolate
[0066] 1 cup chocolate chips
[0067] t4 cup toasted almonds (small chips)
[0068] ; tablespoon cinnamon
[0069] 1/4 tablespoon vanilla extract
[0070] In one embodiment, the above ingredients may be
admixed and heated to a temperature sufficient to melt or liquefy, preferably avoiding boiling for an extended period and then poured into a container to cool.
[0071] In another embodiment, live bacterium, in accordance
with safety requirements or limitations, may be added following cooling (e.g., as a coating). It will be appreciated that adding the bacterium may be limited by applicable safety
precautions and may reduce the shelf life of the product.
[0072] Although the embodiments of this disclosure have been described with respect to certain exemplary embodiments, it is
to be understood that the specific embodiments are for purposes of illustration and not limitation, as other variations will
occur to those of skill in the art.
14 SUBSTITUTE SHEET (RULE 26)

Claims (18)

1. A use of a product in the preparation of a medicament for promoting a desired oral
microbiota to treat an allergy related respiratory condition in a subject in need of such
treatment comprising:
providing a prebiotic edible composition comprising an amino acid containing
ingredient comprising individual molecules of L-arginine and a sugar containing ingredient,
the sugar comprising one or more of monosaccharides, disaccharides, oligosaccharides, and
polysaccharides;
removing a biofilm from surfaces within an oral cavity by heating the inside of the
oral cavity to a temperature of about 37 deg C. to about 55 deg C.;
wherein following removal of the biofilm, the composition is provided contained and
at least partially dissolved within an oral cavity of the subject for a period of at least from
about 10 seconds to about an hour on a daily basis of at least two consecutive days to
promote an increased concentration of selected oral microbiota, the selected microbiota
comprising Veillonella and Streptococcus, to thereby treat an allergy related respiratory
condition.
2. The use of claim 1, wherein the composition is provided in a carrier.
3. The use of claim 2, wherein the carrier comprises a solid, powder or liquid.
4. The use of claim 2, wherein the carrier comprises one or more of a chewable tablet, an
edible capsule, and a hygienic paste, and an edible food.
5. The use of claim 1, wherein the composition is provided within the oral cavity
from a period of from about 2 consecutive days to about 60 consecutive days.
6. The use of claim 1, wherein heating the inside of the oral cavity comprises periodic
oral rinsing with a heated liquid, each rinsing for about 10 seconds to about 1 minute over a
period of from about 5 to about 15 minutes.
7. The use of claim 1, wherein removal of a biofilm comprises heating the inside of the
oral cavity including at least one of rinsing, brushing, and rubbing the oral cavity with a
heated liquid.
8. The use of claim 1, wherein the at least one amino acid further comprises at least one
of L-cysteine, DL-aspartic acid, L-glutamic acid, L-serine, and L-tyrosine.
9. The use of claim 1, wherein the amino acid containing ingredient is present in the
composition at a weight percent level of from about 0.1 wt.% to about 99.9 wt.%.
10. The use of claim 1, wherein the composition further comprises a sugar containing
ingredient, the sugar comprising one or more of monosaccharides, disaccharides,
oligosaccharides, and polysaccharides.
11. The use of claim 10, wherein the sugar comprises one or more of mannose, lactose,
malibiose, maltose, cellobiose, trehalose, raffinose.
12. The use of claim 10, wherein the composition further comprises polysaccharide
polymers.
13. The use of claim 12, wherein the polysaccharide polymers comprise one or more of
pullulan and inulin.
14. The use of claim 10, wherein the sugar is present in the composition at a weight
percent level of from about 0.1 wt. % to about 99.9 wt. %.
15. The use of claim 10, wherein the sugar is present in the composition at a weight
percent level of from about 0.5 wt. % to about 95 wt. %.
16. The use of claim 10, wherein at least one of the composition and oral cavity further
comprises live bacterium comprising a lactic acid producing bacterium and a lactate
fermenting bacterium.
17. The use of claim 1, wherein the sugar comprises one or more of mannose, lactose,
malibiose, maltose, cellobiose, trehalose, raffinose.
18. The use of claim 1, wherein at least one of the edible composition and oral cavity
further comprises live bacterium comprising a lactic acid producing bacterium and a lactate
fermenting bacterium.
AU2018257624A 2017-04-24 2018-04-13 Oral microbiota promoting composition and method Active AU2018257624B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/495,188 US9795579B1 (en) 2017-04-24 2017-04-24 Oral microbiota promoting method
US15/495,188 2017-04-24
PCT/US2018/027604 WO2018200223A1 (en) 2017-04-24 2018-04-13 Oral microbiota promoting composition and method

Publications (2)

Publication Number Publication Date
AU2018257624A1 AU2018257624A1 (en) 2019-12-05
AU2018257624B2 true AU2018257624B2 (en) 2021-07-08

Family

ID=60082814

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018257624A Active AU2018257624B2 (en) 2017-04-24 2018-04-13 Oral microbiota promoting composition and method

Country Status (7)

Country Link
US (2) US9795579B1 (en)
EP (1) EP3609488A4 (en)
JP (2) JP7290869B2 (en)
KR (2) KR20190141707A (en)
CN (1) CN110520119A (en)
AU (1) AU2018257624B2 (en)
WO (2) WO2018200223A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9795579B1 (en) * 2017-04-24 2017-10-24 Knoze Jr. Corporation Oral microbiota promoting method
US10842811B2 (en) 2018-02-28 2020-11-24 The Trustees Of Columbia University In The City Of New York Inulin for preventing antibiotic resistant infection and pathogen colonization
CN114760976A (en) 2019-12-16 2022-07-15 高露洁-棕榄公司 Oral care composition containing inulin
EP4084784A4 (en) * 2020-01-13 2024-01-17 Monash University COMPOSITIONS AND METHODS
JP2022103980A (en) * 2020-12-28 2022-07-08 サンスター スイス エスエー Composition for oral cavity
WO2022145325A1 (en) * 2020-12-28 2022-07-07 サンスター スイス エスエー Composition for oral cavity

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0441119A2 (en) * 1990-01-09 1991-08-14 Richard D. Levere The use of L-Arginine in the treatment of hypertension and other vascular disorders
RU2375923C2 (en) * 2008-01-18 2009-12-20 ЗАО "Академия-Т" Special protein product for sport feeding
RU2426438C2 (en) * 2006-12-06 2011-08-20 ЗАО "Академия-Т" Synbiotic composition for correction of intestinal tract microbiocenosis abnormalities and enhancement of organism general resistivity and its production methods (versions)
WO2014200334A1 (en) * 2013-06-14 2014-12-18 N.V. Nutricia Synbiotic composition for treatment of infections in allergic patients
CN105901678A (en) * 2016-04-15 2016-08-31 邵素英 Agaric probiotic functional food
US20160304886A1 (en) * 2013-09-24 2016-10-20 The Regents Of The University Of Michigan Compositions and method for destabilizing, altering, and dispersing biofilms

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790678B1 (en) * 1999-08-17 2010-09-07 Immunopath Profile, Inc. Composition with anti-inflammatory, protein synthesizing, enzyme deficiency activating genetic therapy and anti-cancer activity and methods of use
BR0107933A (en) * 2000-01-28 2004-01-06 Procter & Gamble Tasty arginine compounds and their uses for cardiovascular health
US20040258630A1 (en) * 2003-06-23 2004-12-23 Boyd Thomas J. Antiplaque breath freshening consumable film
EP1818053A4 (en) * 2004-11-02 2008-02-27 Ajinomoto Kk Preventive/remedy for allergic diseases
SI2114421T1 (en) * 2007-03-05 2018-04-30 Om Pharma Bacterial extract for respiratory disorders and proces for its preparation
JP5554994B2 (en) * 2007-11-19 2014-07-23 株式会社カネカ Lactic acid bacteria-containing preparation
US20100055082A1 (en) * 2008-09-04 2010-03-04 Jacques Alain Bauer Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof
AU2012237345A1 (en) * 2011-03-31 2013-09-19 Nestec S.A. Nutritional compositions for increasing arginine levels and methods of using same
CN103458890A (en) * 2011-04-12 2013-12-18 雀巢产品技术援助有限公司 Nutritional compositions including branched chain fatty acids and methods of using same
WO2014151329A1 (en) * 2013-03-15 2014-09-25 Aerodesigns, Inc. Particles for aerosolizing apparatus
CN103520719B (en) * 2013-10-24 2016-11-23 邹潮 A kind of buccal antibody product and preparation method thereof
AU2013408772B2 (en) * 2013-12-27 2017-04-20 Colgate-Palmolive Company Prebiotic oral care compositions containing amino acids
CN104435000A (en) * 2014-11-12 2015-03-25 江南大学 Application of lactic acid bacteria for treating bronchial asthma
KR101734653B1 (en) * 2015-06-23 2017-05-11 서울대학교산학협력단 Pharmaceutical composition comprising aminoglycoside and probiotics for preventing or treating aphthous stomatitis
CN108882740A (en) * 2015-12-29 2018-11-23 N·V·努特里奇亚 Fermented formulations containing non-digestible oligosaccharides
CN106857856A (en) * 2017-01-14 2017-06-20 威海紫光科技园有限公司 It is a kind of to be beneficial to the compound probiotic product of respiratory system
US9795579B1 (en) * 2017-04-24 2017-10-24 Knoze Jr. Corporation Oral microbiota promoting method
US10398670B2 (en) * 2017-04-24 2019-09-03 Knoze Jr. Corporation Oral microbiota promotion for oral and/or sinus infections

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0441119A2 (en) * 1990-01-09 1991-08-14 Richard D. Levere The use of L-Arginine in the treatment of hypertension and other vascular disorders
RU2426438C2 (en) * 2006-12-06 2011-08-20 ЗАО "Академия-Т" Synbiotic composition for correction of intestinal tract microbiocenosis abnormalities and enhancement of organism general resistivity and its production methods (versions)
RU2375923C2 (en) * 2008-01-18 2009-12-20 ЗАО "Академия-Т" Special protein product for sport feeding
WO2014200334A1 (en) * 2013-06-14 2014-12-18 N.V. Nutricia Synbiotic composition for treatment of infections in allergic patients
US20160304886A1 (en) * 2013-09-24 2016-10-20 The Regents Of The University Of Michigan Compositions and method for destabilizing, altering, and dispersing biofilms
CN105901678A (en) * 2016-04-15 2016-08-31 邵素英 Agaric probiotic functional food

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARBES,JR. et al., "Oral pathogens and allergic disease: Results from the Third National Health and Nutrition Examination Survey", The Journal of Allergy and Clinical Immunology, (2006-11), vol. 118, no. 5, pages 1169 - 1175 *
CARD et al., "Modulation of Allergic Airway Inflammation by the Oral Pathogen Porphyromonas gingivalis", Infection and Immunity, (2010-06), vol. 78, no. 6, pages 2488 - 2496 *
JESSICA E. KOOPMAN ET AL, "Changes in the oral ecosystem induced by the use of 8% arginine toothpaste", ARCHIVES OF ORAL BIOLOGY., GB, (2017-01-01), vol. 73, doi:10.1016/j.archoralbio.2016.09.008, ISSN 0003-9969, pages 79 - 87 *

Also Published As

Publication number Publication date
KR20190141707A (en) 2019-12-24
JP7290869B2 (en) 2023-06-14
AU2018257624A1 (en) 2019-12-05
JP2020517746A (en) 2020-06-18
JP2021167338A (en) 2021-10-21
WO2019055665A1 (en) 2019-03-21
US9795579B1 (en) 2017-10-24
EP3609488A1 (en) 2020-02-19
EP3609488A4 (en) 2020-05-13
KR20220034925A (en) 2022-03-18
CN110520119A (en) 2019-11-29
US11364217B2 (en) 2022-06-21
WO2018200223A1 (en) 2018-11-01
US20180303781A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
US11083760B2 (en) Oral microbiota composition for oral and/or sinus infections
AU2018257624B2 (en) Oral microbiota promoting composition and method
JP5906011B2 (en) Oral composition
JP4440095B2 (en) Anti-periodontal disease bacteria composition
HK1215682A1 (en) Compositions, uses and methods for treating or preventing dental caries
JP2023168549A (en) Agent for inhibiting oral cavity pathogenic bacterium from growing, composition for oral cavity, and accelerator
CN101321560B (en) Chewable compositions with fast release magnolia bark extract
Clark et al. Effect of commonly prescribed liquid medications on Streptococcus mutans biofilm. An in vitro study
Badiyani et al. Chocolate disinfectant: effectiveness of cocoa bean husk extract on Streptococcus mutans in used toothbrushes
US10398670B2 (en) Oral microbiota promotion for oral and/or sinus infections
Achmad et al. Chewable Lozenges using White Shrimp Waste (Litopenaeus vannamei) in Reduce Colonization of Bacteria Streptococcus mutans in the Case of Early Childhood Caries.
US11896630B2 (en) Composition for a formulated oral prebiotic edible composition
US11083759B2 (en) Oral microbiota transformation for the relief of immune system associated inflammations
US10471033B2 (en) Oral microbiota promotion for immune system associated inflammations
JP2723551B2 (en) Oral composition
JP6293177B2 (en) Oral composition
EP4447989A1 (en) Oral care composition comprising enzymes
US20220304967A1 (en) Oral microbiota promoting composition cross-reference to related applications
KR101295242B1 (en) Antibacterial Composition for Inhibiting Oral Bacteria comprising extract of Dianthus superbus
Jaffar et al. Factors responsible for dental caries among patients and its management
Maguire Dental health
Pomakova et al. Clinical Study of the Change of pH Level in the Supragingival Plaque in Children after Taking Homeopathic Remedies
Bashir Sweet Bacterial Treats that Prevent Tooth Decay-A Newer Probiotic Approach.
JP2009274957A (en) Bactericidal agent against pathogenic bacterium of periodontal disease comprising red longhorn frass as active ingredient
JPH08154585A (en) Composition for oral cavity for inhibition of sticking and elimination of periodontal pathogenic bacterium

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)